Ilisa Halpern Paul, MPP

Ilisa offers her insider perspective and insights on:

• The legislative and regulatory outlook for various healthcare issues
• The specific priorities and strategies with respect to the Democratic House, the Republican Senate, and the Trump Administration
• Changes to leadership and membership of key congressional committees for healthcare and what those changes mean for the policy agenda
• The future of the Patient Protection and Affordable Care Act (ACA health reform)
• The financial and programmatic outlook for the Medicaid and Medicare programs
• What is likely coming and how best to leverage opportunities and mitigate threats.

Currently, she is speaking to healthcare providers about the outlook on top-of-mind concerns such as the 340B drug pricing program, rural health, surprise billing, value-based care, drug pricing reform, hospital consolidation, maternal health initiatives, the new home health and home infusion payment system, digital health, telehealth, and behavioral health and substance use disorder treatment.

Ilisa Halpern Paul is president of the District Policy Group, the boutique lobbying, public policy, and advocacy team at international law firm Drinker Biddle & Reath LLP.

With more than 25 years of experience in government relations, advocacy, and policy making in for-profit, nonprofit, academic, federally funded, and government settings, she leads a bipartisan team of 15 government relations professionals out of the firm’s Washington, DC office. Ilisa advises and represents companies, nonprofit organizations, trade associations, and coalitions in advancing their federal legislative and regulatory priorities.

A highly sought-after speaker and adviser, Ilisa provides insight, analysis, and advice with respect to understanding and successfully navigating the current policy and political environment. She presents to boards of directors, organizational trustees, leadership groups, conferences, and other audiences regarding the results of the 2018 election and its implications for the 116th United States Congress which convened on January 3, 2019. She provides specific insights with respect to issues that may be addressed by the Congress and the Trump Administration over the next two years.

Ilisa’s expertise is framed by her experience serving on the staff of a U.S. Senator, leading federal lobbying departments for two national healthcare organizations, and working over the past 17 years as a consultant to health and hospital systems, patient advocacy organizations, medical technology and life sciences companies, and other entities working in the healthcare industry.

Prior to her work as a government relations consultant, Ilisa served as director of federal government Relations for the American Cancer Society and also worked as director of federal affairs with the American Public Health Association (APHA). Ilisa began her Washington, D.C. career working on the policy staff of U.S. Senator Dianne Feinstein following research assistant positions with Adeza Biomedical and the UCLA Pediatric Pain Program.